Tiger Brokers

BUZZ-Moderna shares fall after birth defect vaccine trial misses target

Reuters
Oct 23
BUZZ-<a href="https://laohu8.com/S/MRNA">Moderna</a> shares fall after birth defect vaccine trial misses target

** Shares of biotechnology company Moderna MRNA.O down 3.5% to$25.91 premarket after co halts development of birth defect vaccine following trial setback

** Experimental Cytomegalovirus (CMV) vaccine mRNA-1647 showed efficacy of 6% to 23% in 7,500 women, missing company’s target in a last-stage trial

** CMV can cause birth defects if passed from mother to baby during pregnancy; no approved vaccine to cure it currently exists

* MRNA does not expect the trial goal to break even by 2028

**Co does not expect trial failure to impact 2025 outlook

** Four out of 25 analysts rate stock "buy", 16 "hold" and five rate it "sell" or below; median PT at $30.50 - data compiled by LSEG

** As of Wednesday's close, MRNA shares down 35.43% YTD,

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10